The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience.
Saved in:
| Title: | The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience. |
|---|---|
| Authors: | Olszewska-Szopa, Magdalena1 (AUTHOR), Ożańska, Agnieszka1 (AUTHOR) aozanska@usk.wroc.pl, Ożański, Tomasz2 (AUTHOR), Rybka, Justyna1 (AUTHOR), Wróbel, Tomasz1 (AUTHOR) |
| Source: | Leukemia & Lymphoma. Jan2024, Vol. 65 Issue 1, p55-61. 7p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
